Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes

Gene Therapy

Volumn 7, Issue 23, 2000, Pages 2028-2035

  Strobel, I ^a   Berchtold, S ^a   Gotze A ^a   Schulze, U ^a   Schuler, G ^a   Steinkasserer, A ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

CTL; Dendritic cells; Immunotherapy; RNA transfection

Indexed keywords

GREEN FLUORESCENT PROTEIN; HLA ANTIGEN CLASS 1; LIPOSOME; MATRIX PROTEIN; PLASMID DNA; TUMOR ANTIGEN; VIRUS DNA; VIRUS PROTEIN; VIRUS RNA;

ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CELL CLONE; CELL PROLIFERATION; CELL STIMULATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA TRANSFECTION; DNA TRANSFER; ELECTROPORATION; GENE TECHNOLOGY; GENE TRANSFER; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VITRO STUDY; INFLUENZA VIRUS; MEMORY CELL; MONOCYTE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REPORTER GENE; RNA TRANSCRIPTION;

ANTIGENS, VIRAL; CLONE CELLS; DENDRITIC CELLS; DNA; ELECTROPORATION; GENE EXPRESSION; GENE THERAPY; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; LIPOSOMES; LUMINESCENT PROTEINS; LYMPHOCYTE ACTIVATION; RNA; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VIRAL MATRIX PROTEINS;

EID: 0034517560     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301326     Document Type: Article

References (44)

1. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes
2. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes
3. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
4. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer
5. Dendritic cells and the control of immunity
6. Dendritic cells
7. Dendritic cells as adjuvants for immune-mediated resistance to tumors
8. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity
9. Vaccination of patients with B cell lymphoma using autologous antigen-pulsed dendritic cells
10. Phase I clinical trial: T cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
11. Vaccination of melanoma patients with peptideor or tumor lysate-pulsed dendritic cells
12. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGe-3 and presented by HLA-A1
13. Intracutaneous vaccination with Mage-3.A1 peptide-pulsed mature monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
14. Rapid generation of broad T cell immunity in humans after a single injection of mature dendritic cells
15. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
16. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen
17. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia
18. Induction of antitumor immunity using bone marrow-generated dendritic cells
19. Dendritic cells in anti-tumor immune responses. I. Defective antigen presentation in tumor-bearing hosts
20. Human tumor antigens recognized by T lymphocytes
21. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene
22. Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity
23. ++ human cord blood cells generate T cells expressing high levels of the retroviral encoded green fluorescent protein marker in vitro
24. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity
25. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination
26. A comparison of gene transfer methods in human dendritic cells
27. High efficiency adenovirus-mediated gene transfer to human dendritic cells
28. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells
29. Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors
30. Vaccinia virus inhibits the maturation of human dendritic cells: A novel mechanism of immune evasion
31. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes
32. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing and IFN-a
33. Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation
34. Nonviral transfection of distinct types of human dendritic cells: High-efficiency gene transfer by electroporation into hematopoietic progenitor-, but not monocyte-derived dendritic cells
35. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
36. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
37. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA
38. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells
39. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies
40. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro
41. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions
42. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood
43. + T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens
44. Efficient expression of the tumor-associated antigen MAGE-3 in human dendritic cells using an avian influenza virus vector